Passive Surveillance in Pharmacovigilance: Pharmacovigilance plays a pivotal role in ensuring the safety of medicinal products, including vaccines, throughout their life cycle. Among the various techniques employed in pharmacovigilance, passive surveillance remains one of the most extensively used due to its feasibility, broad scope, and utility in the early detection of safety signals.
Understanding Passive Surveillance
Passive surveillance refers to a system of safety monitoring in which adverse events or suspected reactions are reported on a voluntary basis. This type of surveillance relies on individuals—usually healthcare professionals (HCPs), consumers, or patients—to identify and report adverse events to the concerned regulatory authority or marketing authorization holder (MAH), without any active solicitation or intervention.
Passive surveillance is a reactive method. Reports are generated based on spontaneous observations and are not a result of structured or organized data collection. Despite its limitations, passive surveillance is valuable for hypothesis generation, identifying rare adverse events, detecting previously unknown risks, and monitoring known adverse events in real-world settings.
1. Spontaneous Reporting
Spontaneous reporting involves the unsolicited submission of adverse event reports to national regulatory authorities or pharmaceutical companies by healthcare professionals, patients, caregivers, or other parties. These reports are typically submitted through paper forms, online portals, phone calls, or mobile apps.
Spontaneous reporting systems (SRSs) serve as the cornerstone of post-marketing pharmacovigilance and are the primary mechanism through which safety signals are detected.
Examples of Spontaneous Reporting Systems Worldwide:
| Country/Region | System Name | Managed By |
| United States | VAERS (Vaccine Adverse Event Reporting System) | CDC & FDA |
| European Union | EudraVigilance | European Medicines Agency (EMA) |
| United Kingdom | Yellow Card Scheme | Medicines and Healthcare Products Regulatory Agency (MHRA) |
| Canada | Canada Vigilance Program | Health Canada |
| India | PvPI (Pharmacovigilance Programme of India) | Indian Pharmacopoeia Commission (IPC) |
| Global | VigiBase® | WHO–Uppsala Monitoring Centre (UMC), Sweden |
Key Characteristics:
- Reports may include one or multiple adverse events.
- Data are often submitted without standardized follow-up.
- Not limited to serious events; minor or unexpected events may also be reported.
- Information includes patient demographics, suspected product, event description, reporter details, and timelines.
Significance in Pharmacovigilance:
- Early Detection of Safety Signals: Many critical safety signals (e.g., anaphylaxis after certain vaccines or drug-induced liver injury) were first identified through spontaneous reports.
- Real-World Data: Reflects outcomes in diverse populations and actual usage patterns.
- Risk Management: Helps regulatory agencies in decision-making—such as updating product labeling, issuing warnings, or conducting safety reviews.
Limitations:
- Underreporting: It is estimated that less than 10% of actual adverse events are reported, especially non-serious ones.
- Data Quality: Incomplete or inaccurate data often impedes meaningful analysis.
- No Denominator: Since the number of people exposed to the product is unknown, it is not possible to determine incidence or prevalence from spontaneous reports.
- Causality Assessment Difficulties: Spontaneous reports alone cannot establish definitive causal relationships.
2. Case Series
A case series refers to a group of similar adverse event cases that share certain characteristics, such as the same suspected product, similar clinical outcomes, or temporal relationships. It is a descriptive method used to illustrate trends, common patterns, and potential associations.
While a single case report might raise suspicion, a case series allows for aggregation of data, enhancing the ability to observe consistent features or emerging signals that merit further evaluation.
Key Features:
- Cases are often identified from spontaneous reports or clinical observations.
- Not controlled or randomized.
- Typically used to describe the frequency and characteristics of a specific adverse event in relation to a specific product.
Application in Vaccine Pharmacovigilance:
- For example, a case series describing Guillain-Barré Syndrome (GBS) following influenza vaccination may help regulators consider a possible association.
- During the COVID-19 pandemic, case series of myocarditis post mRNA vaccination in young males helped trigger active investigations and risk-benefit assessments.
Strengths:
- Facilitates early hypothesis generation.
- Helps identify clusters or patterns of unusual or rare events.
- May provide supporting evidence for causality when temporal associations, biological plausibility, and consistency are observed.
Limitations:
- No Control Group: Cannot compare outcomes with a non-exposed population.
- Bias: Selection and reporting biases may distort findings.
- No Incidence Calculation: Cannot determine how common an event is among vaccine recipients.
3. Stimulated Reporting
Stimulated reporting is an enhanced form of passive surveillance where reporting is actively encouraged or promoted through targeted efforts. It is implemented during critical periods—such as after the launch of a new vaccine, during public health emergencies, or in response to a safety concern—to increase the volume and timeliness of adverse event reporting.
It acts as a bridge between passive and active surveillance and is often used to enhance vigilance during high-risk scenarios.
Methods of Stimulated Reporting:
- Reminders or Alerts: SMS or email reminders sent to HCPs.
- Educational Campaigns: Distribution of brochures, posters, or digital tools explaining what, how, and when to report adverse events.
- Pre-populated Reporting Forms: Simplifying the reporting process for clinicians.
- Integration in Electronic Health Records (EHRs): Automated alerts or embedded links to reporting portals.
- Temporary Mandates: Sometimes reporting may be required for specific drugs or vaccines under conditional approvals.
Use Cases:
- Introduction of a new vaccine or biological product.
- During a mass immunization campaign, e.g., polio or COVID-19.
- Following widespread media coverage or public concern about a specific safety issue.
- When a known adverse event is suspected to be underreported.
Benefits:
- Higher Reporting Rates: Compared to standard spontaneous systems.
- Improved Sensitivity: Increases the likelihood of capturing rare or serious adverse events.
- Early Risk Characterization: Allows regulators to act quickly when potential threats emerge.
Drawbacks:
- May lead to reporting bias as the volume of reports can be artificially inflated.
- Temporal Spikes in reporting may not reflect actual risk changes.
- Resource Intensive: Requires funding, planning, and coordination.
Overall Utility of Passive Surveillance in Public Health
Despite its limitations, passive surveillance provides a critical foundation for post-marketing safety monitoring. It helps authorities:
- Detect rare and serious AEs that might not surface in clinical trials.
- Monitor known risks in different populations.
- Compare safety profiles across products and formulations.
- Generate hypotheses for further investigation using active surveillance or epidemiological methods.
Passive surveillance often triggers formal investigations, regulatory changes, or label modifications. When supplemented with active surveillance, risk-benefit analyses, and pharmacoepidemiology, it becomes a powerful tool in the ongoing assurance of public safety.
Conclusion
Passive pharmacovigilance methods—especially spontaneous reporting, case series analysis, and stimulated reporting—are integral to the identification and evaluation of vaccine and drug safety signals. Although they rely on voluntary participation and have limitations in quantifying risks, these tools serve as the first line of defense in detecting safety concerns in large populations.
By encouraging better awareness, improving education among healthcare professionals, integrating digital tools, and fostering a culture of safety, we can significantly strengthen passive surveillance systems. Furthermore, combining these approaches with active surveillance ensures a more robust and proactive pharmacovigilance framework that prioritizes patient safety in all phases of a product’s life cycle.